[PMC free article] [PubMed] [Google Scholar] 24
[PMC free article] [PubMed] [Google Scholar] 24. (1) erlotinib, (2) erlotinib plus MK-2206, (3) MK-2206 plus AZD6244, or (4) sorafenib. Tumor gene expression profilingCtargeted next-generation sequencing was performed to evaluate predictive and prognostic biomarkers. Results Two hundred patients, 27% with mut+) tumors, were adaptively Nutlin 3a randomly assigned to erlotinib (n = 22), erlotinib plus…